Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
